To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial

Marieke J. H. Begemann*, Ilse A. Thompson, Wim Veling, Shiral S. Gangadin, Chris N. W. Geraets, Erna van 't Hag, Sanne J. Mueller-Kuperus, Priscilla P. Oomen, Alban E. Voppel, Mark van der Gaag, Martijn J. Kikkert, Jim Van Os, H. Filip E. Smit, Rikus H. Knegtering, Sybren Wiersma, Luyken H. Stouten, Harm J. Gijsman, Lex Wunderink, Anton B. P. Staring, Selene R. T. VeermanAmrita G. S. Mahabir, Jorg Kurkamp, Gerdina H. M. Pijnenborg, Natalie D. Veen, Machteld Marcelis, Koen P. Grootens, Gunnar Faber, Nico J. van Beveren, Agaath Been, Truus van den Brink, Maarten Bak, Therese A. M. J. van Amelsvoort, Andrea Ruissen, Christine Blanke, Karin Groen, Lieuwe de Haan, Iris E. C. Sommer

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number147
Number of pages19
JournalTrials
Volume21
Issue number1
DOIs
Publication statusPublished - 7 Feb 2020

Keywords

  • Antipsychotic medication
  • first episode psychosis
  • Maintenance
  • Treatment
  • Discontinuation
  • Tapering
  • global functioning
  • Randomized controlled trial
  • REMITTED 1ST-EPISODE PSYCHOSIS
  • SUBJECTIVE EXPERIENCE
  • RATING-SCALE
  • PSYCHOMETRIC PROPERTIES
  • RECEPTOR OCCUPANCY
  • SCHIZOPHRENIA
  • DISCONTINUATION
  • RELIABILITY
  • INTERMITTENT
  • SENSITIVITY

Cite this